Performance Comparison
Portfolio Performance Comparison
| Name | YTD Return | 1Yr AR | 3Yr AR | 5Yr AR | 10Yr AR | 15Yr AR | 20Yr AR | Common | Inception |
|---|---|---|---|---|---|---|---|---|---|
| MGCLD (MGC Pharmaceuticals Limited) | NA | 4,077.22% | 150.48% | 61.54% | NA | NA | NA | … | … |
Data as of 01/16/2024, Common starting date is 02/22/2017
More Performance Analytics Comparison
| Name | Start Date | End Date |
|---|---|---|
| MGCLD (MGC Pharmaceuticals Limited) | 02/22/2017 | 01/16/2024 |
| Last 1 Week | 1 Yr | 3 Yr | 5 Yr | 10 Yr | 15 Yr | 20 Yr | Common | Inception | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annualized Return (%) | 0.00 | 4,077.22 | 150.48 | 61.54 | NA | NA | NA | … | … | 0.00 | 2,344.44 | -50.00 | 35.00 | -20.00 | -1.57 | -68.25 | 100.00 |
| Sharpe Ratio | NA | 5.20 | 0.33 | 0.15 | NA | NA | NA | … | … | 0.00 | 3.25 | -0.21 | 0.23 | -0.05 | -0.02 | -0.32 | 0.70 |
| Standard Deviation(%) | NA | 735.25 | 457.69 | 405.71 | NA | NA | NA | … | … | NA | 740.54 | 245.81 | 152.34 | 405.85 | 178.51 | 217.42 | 177.30 |
| Draw Down(%) | NA | 94.00 | 99.37 | 99.37 | NA | NA | NA | … | … | 0.00 | 95.56 | 82.00 | 73.23 | 88.60 | 60.00 | 85.71 | 73.00 |
| Yield(%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | … | … | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Data as of 01/16/2024, Common starting date is 02/22/2017
Performance Comparison Chart
Annualized Rolling Returns Comparison (Minimum)
| Ticker/Portfolio Name | 3 Year | 5 Year | 10 Year | 15 Year |
|---|---|---|---|---|
| MGCLD (MGC Pharmaceuticals Limited) |
-61.01%
Aug 2020 – Aug 2023 |
-50.11%
Jul 2018 – Jul 2023 |
0.00%
NA |
0.00%
NA |
Annualized Rolling Returns Comparison (Maximum)
| Ticker/Portfolio Name | 3 Year | 5 Year | 10 Year | 15 Year |
|---|---|---|---|---|
| MGCLD (MGC Pharmaceuticals Limited) |
296.03%
Oct 2020 – Oct 2023 |
99.05%
Oct 2018 – Oct 2023 |
0.00%
NA |
0.00%
NA |
Annualized Rolling Returns Comparison Chart
